Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: A population-based study by Reeve, Bryce B. et al.
Impact of diagnosis and treatment of clinically-localized prostate
cancer on health-related quality of life for older Americans: a
population-based study
Bryce B. Reeve, PhD1, Angela M. Stover, MA2, Roxanne E. Jensen, PhD3, Ronald C. Chen,
MD, MPH4, Kathryn L. Taylor, PhD3, Steven B. Clauser, PhD5, Sean P. Collins, MD, PhD6,
and Arnold L. Potosky, PhD3
1Lineberger Comprehensive Cancer Center; Department of Health Policy and Management,
Gillings School of Global Public Health, University of North Carolina at Chapel Hill
2Department of Health Behavior and Health Education, Gillings School of Global Public Health,
University of North Carolina at Chapel Hill
3Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center,
Georgetown University
4Department of Radiation Oncology, University of North Carolina at Chapel Hill
5Outcomes Research Branch, Applied Research Program, Division of Cancer Control and
Population Sciences, National Cancer Institute
6Department of Radiation Oncology, Georgetown University Hospital
Abstract
Background—Few studies have measured the longitudinal change in health-related quality of
life (HRQOL) of prostate cancer patients starting prior to cancer diagnosis, or provide
simultaneous comparisons with a matched non-cancer cohort. Our study addresses these gaps by
providing unique estimates of the effects of a cancer diagnosis on HRQOL accounting for the
confounding effects of ageing and comorbidity.
Methods—The Surveillance, Epidemiology, and End Results registry data were linked with the
Medicare Health Outcomes Survey (MHOS) data. Eligible patients (n=445) were Medicare
beneficiaries, aged 65 years and older, from 1998–2003 whose first prostate cancer diagnosis
occurred between their baseline and follow-up MHOS. Using propensity score matching, we
identified 2225 participants without cancer in the MHOS. Analysis of covariance models were
used to estimate changes in HRQOL as assessed with the Short Form-36 and activities of daily
living scale.
Results—Before diagnosis, prostate cancer patients reported similar HRQOL to men without
cancer. Following diagnosis, men with prostate cancer experienced significant decrements in
physical, mental, and social aspects of their lives relative to controls, especially within the first 6
months from diagnosis. For men surveyed beyond one year after diagnosis, HRQOL was similar
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to controls. However, we observed an increased risk for major depressive disorder among men
undergoing either conservative management or external beam radiation.
Conclusions—These findings illustrate the time-sensitive nature of decline in HRQOL after a
cancer diagnosis and enhance our understanding of the impact of prostate cancer diagnosis and
treatment on older men’ physical, mental, and social well-being.
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Introduction
In 2011, an estimated 240,890 men were diagnosed with prostate cancer, with 62% of cases
diagnosed in men older than 65 years of age.1 Treatments for localized prostate cancer
include: radical prostatectomy, external beam radiation therapy, brachytherapy, and
conservative management (androgen deprivation therapy alone or no treatment).2 While
treated men often experience excellent long-term survival, the treatments can have an impact
on men’s health-related quality of life (HRQOL).2–4
A large number of studies have documented the effects of prostate cancer and its treatment
on HRQOL; however, these studies have collected prospective HRQOL data starting after a
prostate cancer diagnosis.5–9 To our knowledge, only our published study has measured the
impact with a baseline HRQOL assessment prior to prostate cancer diagnosis to capture the
true prospective impact of the disease on patients’ HRQOL.10 In addition, longitudinal
comparison data for men without cancer have rarely been collected,11 limiting the ability to
assess the marginal effects of prostate cancer on the elderly for whom it may be difficult to
attribute longitudinal declines in HRQOL to prostate cancer accounting for ageing and other
chronic comorbid conditions.
The 2007 linkage of data from the National Cancer Institute (NCI)’s Surveillance,
Epidemiology, and End Results (SEER) program with the Centers for Medicare & Medicaid
Services’ (CMS) Medicare Health Outcomes Survey (MHOS) provides a unique opportunity
to measure the burden of prostate cancer and treatment on older men’s lives.12 The
population-based SEER cancer registries provide detailed clinical data on incident cancers
including stage and initial treatment. The MHOS provides data on patients’ experiences and
perspectives as they relate to physical, mental, and social well-being.
This study will estimate the prospective change in HRQOL from before to after prostate
cancer diagnosis for men aged 65 years and older, and to compare their changes relative to a
similar cohort of men without cancer. This report differs from our prior study using the
SEER-MHOS dataset that compared HRQOL among 9 different cancer types.10 Here we
focus on prostate cancer-specific clinical characteristics such as treatment type, stage of
disease, and time since diagnosis likely to be important influences on changes in HRQOL.
Methods
Study Participants
Under the CMS and NCI collaboration, survey data from CMS’ MHOS13 were linked in
2007 with data from NCI’s SEER cancer registries.14 During the study period from 1998 to
2003, the MHOS was administered annually to a random sample of 1000 Medicare
beneficiaries from each Medicare Advantage Organization (MAO) under contract with
CMS. Each participant completed a baseline and two year follow-up survey if he remained
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in the same managed care plan. An overview of the SEER–MHOS data linkage is provided
elsewhere.10,12
Four MHOS cohorts were included in the study with baseline years from 1998 to 2001 and
2-year follow-up surveys. Response rates for the baseline MHOS ranged from 64% to 72%
and follow-up rates ranged from 76% to 85%, resulting in a sample size of 11,683 MHOS
respondents linked to SEER.12
Our study cohort included those prostate cancer patients whose first SEER-confirmed
diagnosis occurred after their baseline and before the follow-up MHOS. We identified 467
eligible men with prostate cancer in this manner. We excluded 22 men diagnosed with
regional or metastatic prostate cancer, resulting in a final sample of 445 men. The average
time from baseline MHOS to prostate cancer diagnosis was 11.5 months (SD = 7.1) and
from prostate cancer diagnosis to follow-up survey was 12.6 months (SD = 7.1).
We selected non-cancer controls (n=16,397 men) who responded to both a baseline and
follow-up MHOS and who resided in the same SEER region and participated in the same
managed care plans as the cancer patients. Using propensity score matching
procedures,15–17 we matched 5 controls to each cancer case to balance the proportion of
patient and survey characteristics as well as pre-existing comorbid conditions between the
groups.10,18,19 This resulted in 2,225 controls matched to 445 men with prostate cancer.
Data Collected
The MHOS provides self-reported data on sociodemographics (education, age, race and
ethnicity, smoking status, marital status), survey characteristics (self-report or proxy, mail or
phone-interview), HRQOL, clinical symptoms, and chronic medical conditions.20 While the
study would be more homogeneous by excluding proxy reporting and men who switched
assessment modes from baseline to follow-up, these data were kept in the analyses in an
attempt to capture the extent of HRQOL changes, including those whose HRQOL may have
been poor enough to require a proxy response. These variables were controlled for in the
regression models.
The MHOS includes the Medical Outcomes Study Short Form-36 (MOS SF-36, version
1);21 a HRQOL measure widely used in medicine.10,22 The SF-36 includes eight subscales:
physical functioning, role-physical, bodily pain, general health, vitality, social functioning,
role-emotional, and mental health. The subscales produce a physical component summary
and mental component summary scores. SF-36 scores are normalized to the general US
population (mean = 50, standard deviation = 10). Higher scores indicate better HRQOL. A
change in SF-36 scores of at least a half standard deviation (i.e., 5 points) is considered
clinically meaningful.23
The MHOS also includes a measure of activities of daily living (ADL) which assesses
difficulties with getting in or out of chairs, dressing, walking, using the toilet, eating, and
bathing. Each ADL is reviewed individually and summed together with higher scores
reflecting more limitations.
The MHOS includes a question about urinary incontinence, which is typically impacted by
treatments for prostate cancer. However, the MHOS did not include any items on sexual or
bowel function, two other key domains for this disease.
The MHOS includes three items from the Diagnostic Interview Schedule (DIS).24 Together
with a question from the SF-36 mental health subscale to capture more recent depressive
mood, an indicator was developed for risk of major depressive disorder (MDD) based on the
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algorithm from a published study.25 This MDD indicator is more conservative than the
MHOS website recommendation that a positive screen for MDD is an affirmative response
to at least one of the three DIS questions.20
The survey included questions about the presence of multiple chronic medical conditions.
We grouped these according to whether they were “pre-existing” diagnosed conditions (i.e.,
before baseline survey) versus “newly diagnosed” conditions (i.e., between baseline and
follow-up survey). See Table 1 for list of conditions. We summed the comorbidities
applying weights based on the association of each condition with physical and mental
aspects of HRQOL. Development of the physical and mental weighted comorbidity indices
are described in a previous study.10
SEER provided information regarding stage of diagnosis, date of diagnosis, and initial
treatment received.14 Among our localized cases, the clinical extent of disease was classified
according to the following categories used in clinical practice: T1 (clinically inapparent or
incidentally detected disease); T2 (clinically or radiographically apparent disease); T2
prostatic apex (extension to prostatic apex); T1 or T2 (i.e., insufficient information to
classify); or unstaged based on lack of any clinical extension information. Time from SEER-
confirmed cancer diagnosis to the follow-up MHOS survey was categorized from 0–6, 7–12,
13–18, and 19 or more months to allow for comparison of HRQOL in patients surveyed at
different points in their post-diagnosis trajectory. We categorized treatments into: radical
prostatectomy (including those who also received adjuvant radiation therapy), external beam
radiation therapy (EBRT), brachytherapy, or conservative management (defined as the
absence of documented curative intent surgery or radiation treatments). Because neither
SEER nor Medicare includes data on the use of outpatient-based hormonal therapy or
Androgen Deprivation Therapy (ADT), it is likely that a sizable proportion of men in our
conservative management group did receive such therapy. SEER contains nearly complete
data on surgery, but there has been recent evidence of a slight under-ascertainment of
radiotherapy.26,27
Statistical Analysis
A mixed-effect analysis of covariance (ANCOVA) model was used to estimate the change
in HRQOL scores adjusting for baseline scores. The model adjusted for clustering for
respondents enrolled in the same MAO and for the five controls matched to each cancer
patient.28 The model included patient characteristics, comorbidities, and survey
characteristics, listed in Table 1, as covariates. Models were tested to look for differences in
HRQOL by treatment type and time since diagnosis, both as main effects and interactions.
Models that included the variable time since diagnosis alone combined prostate cancer
patients across all treatments; thus significant findings may be weighted by treatment groups
overrepresented in the sample (EBRT and conservative management, see Table 1). All
analyses used SAS version 9.2 (Cary, NC).
Results
Sample Description
The characteristics of the men with prostate cancer (n = 445, categorized by initial
treatment) and their matched controls (n = 2,225) are described in Table 1. No statistically
significant differences were observed on demographic characteristics, survey characteristics,
and pre-existing health conditions after propensity score matching. For newly diagnosed
health conditions (not included in the propensity score model), men with prostate cancer had
a higher percentage of gastro-intestinal disorders than men without cancer (3.19% vs 1.39%,
respectively; p < .01).
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Changes in Physical Health
At baseline, the mean SF-36 physical component summary (PCS) score for the non-cancer
matched controls was 45.6 (SD = 11.2) and for the prostate cancer patients (prior to
diagnosis) was 45.1 (SD = 10.9). These were similar by treatment group and consistent with
age-adjusted US general population 1998 SF-36 norms.29,30
In general, there were few statistically significant differences between the treatment groups
and controls in changes over time for the overall PCS or for the SF-36 sub-domains of
physical function (PF), role-physical (RP), or bodily pain (BP). The exception was that for
both the EBRT and conservative management groups we found a statistically significant
decline (adjusted mean change = −3.9 and −3.6, p < .01, respectively) in general health (GH)
relative to the matched controls (mean change = −1.7).
We next examined the changes in patients’ HRQOL relative to controls for patients
classified by the time from diagnosis to their follow-up survey (Figure 1). Men surveyed
within six months from diagnosis had statistically worse overall PCS scores (mean change
−4.9 versus −2.1 in controls; p < .01), RP (−7.6 versus −3.0; p < .01), and GH (−5.0 versus
−1.7; p < .01). Prostate cancer patients surveyed from 7–12 months after diagnosis also
experienced significantly decreased RP (−6.3; p = .046) and GH (−3.5; p = .03) relative to
controls. For PCS, RP, and GH, we did not find an interaction of treatment group and time
since diagnosis. When both variables were included in the model, time since diagnosis but
not treatment remained significantly associated with decreased physical health.
The prostatectomy group experienced a statistically significant improvement relative to
controls (p = .03) in overall ADL from baseline (0.69 change compared with 0.61 on 0 to 6
scale) to follow-up (mean 0.38 compared with 0.88). The prostatectomy group reported
improvements after diagnosis in bathing, dressing, eating, and using the toilet; the controls
reported greater limitations for all the ADLs.
Urinary incontinence was a significant problem reported by all prostate cancer patients
regardless of treatment (Table 2). Each treatment group experienced more urinary
incontinence than controls at the follow-up, with prostatectomy patients reporting the largest
increase in incontinence.
Changes in Mental Health
At baseline, the mean SF-36 MCS score for the non-cancer matched controls was 53.5 (SD
= 10.3) and for the cancer patients was 53.4 (SD = 10.1). These were similar by treatment
group and consistent with age-adjusted general US population 1998 SF-36 norms.29,30
Compared to matched controls without cancer, EBRT patients reported significantly larger
declines in mental component summary (MCS) scores (adjusted mean changes of −1.1 and
−3.8, respectively; adjusted p < .01), role emotional (RE) scores (−2.3 and −5.9,
respectively; p < .01), vitality (VT) scores (−1.4 and −3.2, respectively; p = .01), and social
function (SF) scores (−1.4 and −4.2, respectively; p < .01).
Men surveyed 7–12 months from diagnosis had larger declines in MCS (Figure 1; mean
change was −3.7 compared with −1.1 for controls; p = .02) and VT (−3.7 versus −1.4 for
controls; p < .01). SF was also affected by prostate cancer. Among men surveyed within 6
months of diagnosis, the adjusted mean SF change for cases was −3.6 compared with −1.4
for controls (p = .03). Among men 7–12 months from diagnosis, the mean change in SF was
−4.8 relative to −1.4 for controls (p < .01).
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Men in the conservative management group were at greatest risk for major depressive
disorder (MDD) with 13% and 23% classified as at-risk for MDD at baseline and at follow-
up survey, respectively. This was significantly different (OR = 1.9; 95% CI 1.2–3.0) from
matched controls (11% and 14% at baseline and follow-up, respectively). Men with prostate
cancer (all treatments combined) at 19 or more months post-diagnosis had a higher change
in MDD risk with 13% and 24% at risk for MDD at baseline and follow-up, respectively
(OR = 2.2; 95% CI 1.3–3.8). Men receiving EBRT and who were surveyed more than 19
months from diagnosis were at an increased MDD risk than controls (OR = 3.1; 95% CI 1.3
– 7.1). In addition, relative to controls, men in the conservative management group surveyed
from 13–18 months had the largest increased MDD risk (OR = 3.4; 95% CI 1.5 – 7.4); this
increased MDD risk for the conservative management group, relative to controls, continued
for men surveyed after 19 months (OR = 2.5; 95% CI 1.0–6.0).
Discussion
This prospective population-based study evaluated the burden of prostate cancer and
treatment on the lives of American men over 65 years of age. Although prostate cancer
patients surveyed before diagnosis were similar in health status to matched controls, notable
HRQOL decrements following diagnosis occurred in men with cancer, especially those
receiving EBRT or who were conservatively managed. HRQOL decrements were greatest
for those patients surveyed within 6 months of diagnosis when the men were likely
undergoing active treatment. For men surveyed beyond one year after diagnosis, HRQOL
was similar to controls across most HRQOL domains. Our study is among the very few to
examine HRQOL changes before and after a prostate cancer diagnosis and to use a matched
control group of men without cancer. These findings illustrate the time sensitive nature of
variation in physical, mental, and social well-being for men following cancer diagnosis.
Men diagnosed with prostate cancer within 6 months reported significantly larger
decrements in overall physical health relative to controls and experienced more role
limitations due to their poorer general health than matched controls. Each of these changes
in physical health were at least a half standard deviation or higher on the SF-36; representing
a clinically meaningful change.23 Prostate cancer patients surveyed at 12 months from
diagnosis had comparable decrements in physical health with similarly aged men without
cancer. This trend has been observed in other prospective studies where men often returned
to baseline (defined in these studies as after cancer diagnosis but prior to treatment) physical
health levels.7,9
When examining men by treatment type, those receiving EBRT or conservatively managed
reported worse general health than controls. As we did not have information on ADT, it is
likely that a higher percentage of these patients received ADT for months to years following
diagnosis compared with men in the surgery group.31,32 ADT usage is known to cause
fatigue, muscle weakness, and weight gain which may cause a decline in perceived general
health.33 In men undergoing radiation therapy, the late morbidity from treatment with older
EBRT techniques may partly explain this decline.34,35 Recent technical improvements such
as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy
(IGRT) may reduce such an effect36 but were not widely disseminated until after collection
of this data.37,38
Incontinence was significantly higher for men with prostate cancer than those without
cancer; especially men treated with radical prostatectomy. However, even men in the
conservative management group experienced a statistically significant increase in urinary
incontinence at 9.2%. The rates we observed are similar to those reported in the
literature.5–7,9
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An unexpected finding is that men receiving prostatectomy reported improved activities of
daily living relative to matched controls. Further investigation is needed to replicate this
finding and explore potential reasons for improvement.
Differences in changes in mental health were also detected between the prostate cancer
patients and controls. Men who received EBRT reported statistically significant declines,
relative to controls, in overall mental health, limitations in activities because of emotional
problems, social functioning, and increased fatigue. In addition, an unexpected result is that
men who were 19 months or more from cancer diagnosis were approximately 2.2 times
more likely to exhibit elevated risk for a major depressive disorder than men without cancer,
especially in the conservative management and EBRT groups. Other studies found similar
evidence of increased depression in older age prostate cancer survivors.39–42 While ADT
use may be a contributing factor in these treatment groups,43 the impact of prostate cancer
and age-associated physical limitations may also affect depressive mood.41
Limited social functioning was reported for men with prostate cancer within 12 months from
diagnosis but men beyond 12 months reported similar social functioning as those without
cancer, suggesting some adaptation or return to baseline across all treatment groups.
This study has some limitations. The data set was limited to beneficiaries in Medicare
managed care plans. Past studies suggest that enrollees in MAOs have better health status
than fee-for-service beneficiaries44,45 while others have indicated that health status is
similar.46 Additionally, these data do not capture men who disenrolled from a managed care
plan or passed away before responding to the follow-up survey.47 We lack sufficient data to
estimate the effect of response bias; however, the change in HRQOL scores will likely be
worse when considering men who were close to end of life.
Another possible limitation is that the study included men who required a proxy to report
their HRQOL on the MHOS. The concern may be that responses from proxies may be
influenced by their own feelings about and experiences of caring for the cancer patient.48
However, proxies provide critical information for men who are too ill to self-report.48
Removing proxy data may bias the HRQOL results to reflect better HRQOL outcomes from
cancer than what is actually experienced. Proxy reporting was controlled in the regression
models and was associated with poorer HRQOL.
In addition, our cohort was diagnosed and treated between 1998 and 2004; thus we were
unable to include some newer treatments (e.g., robotic prostatectomy and IMRT). Further,
we were unable to include hormonal therapy which has been reported to be associated with
various physical and mental effects, and thus potentially confounds some of our HRQOL
findings.8,49,50
A final limitation is that the MHOS did not include cancer-specific functional measures.
Many studies have shown that treatments for prostate cancer can result in significant
problems. Radical prostatectomy has also been associated with increased sexual
dysfunction.2,7–9,51–53 Both EBRT and brachytherapy have been shown to be associated
with urinary irritative-obstructive symptoms and bowel dysfunction.2,7–9,51–54
Despite these limitations, this SEER-MHOS prostate cancer study provides researchers,
clinicians, patients, and health plans important information. Understanding the HRQOL
effects from prostate cancer and its treatments could allow healthcare providers to better
anticipate and therefore more effectively manage the physical and psychosocial sequelae of
prostate cancer.10 This study showed that the diagnosis of prostate cancer has a significant
impact on health status, especially those receiving EBRT or patients conservatively
managed. This study provides useful benchmarks of the net impact of prostate cancer on
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HRQOL in the presence of ageing, comorbid health conditions, and sociodemographic
factors. Finally, our estimates may also be informative for incorporating health status in
cost-effectiveness analyses of prevention and early detection interventions. Future research
will attempt to replicate these findings when new SEER-MHOS cohorts become available.
Study results will enable healthcare payers and clinicians to actively monitor how
improvements in treatments for prostate cancer may enhance men’s lives.
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Controls 2225 18.56 21.44 1
Prostatectomy 72 13.89 44.44 5.25 (3.05, 9.05)
External Beam 169 20.12 39.64 2.89 (2.00, 4.17)
Brachytherapy 41 14.63 31.71 2.22 (1.05, 4.68)
Conservative Management 163 29.45 38.65 1.92 (1.31, 2.83)
Note:
*
Covariates in model: baseline urinary control score, pre-existing comorbidities, newly developed comorbidities, education, age, race, marital
status (baseline), widowed/divorced/separated between baseline and followup, smoking status, mixed mode, and proxy.
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